Business Context and Reporting Period
Synergy CHC Corp. (SNYR), a Nevada corporation headquartered in Westbrook, Maine, filed this Form 8-K on August 25, 2025, to report the entry into a material definitive agreement. The filing details a public offering of common stock that closed on August 27, 2025.
Key Financial Metrics
- Shares Sold: 1,750,000 shares of Common Stock.
- Offering Price: $2.50 per share.
- Gross Proceeds: $4.375 million.
- Underwriting Discount: 7% of gross proceeds.
- Estimated Total Expenses: Approximately $0.5 million (including discounts and reimbursable expenses).
- Use of Proceeds: Working capital and general corporate purposes.
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to 262,500 additional shares.
Material Changes and Agreements
The primary material change is the completion of the equity offering. The Company entered into an Underwriting Agreement with Bancroft Capital, LLC, as representative. Additionally, the Company issued Representative Warrants to purchase up to 52,500 shares (3% of the offering size) at an exercise price of $2.75 per share. These warrants are subject to a 180-day lock-up and cannot be exercised for 180 days post-pricing. They expire in tranches over three years (25% at year 3, 25% at year 4, 50% at year 5).
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding future performance beyond the stated intent to use proceeds for working capital. The document notes that the Underwriting Agreement contains customary representations, warranties, and indemnification provisions. It explicitly states that the agreement's provisions are not intended as a document for investors to obtain factual information about the Company's current state of affairs.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 7% underwriting discount and estimated $0.5 million in total expenses.
- Confirm the dilution impact of the 1,750,000 shares sold plus the potential 262,500 over-allotment shares.
- Review the terms of the Representative Warrants (52,500 shares at $2.75) and their expiration schedule.
- Check the Company's updated cash position and working capital status post-closing.
- Examine the final prospectus (File No. 333-289645) for detailed risk factors not summarized in this 8-K.